MoonLake Immunotherapeutics (MLTX) Stock Profile & Financial OverviewMoonLake Immunotherapeutics
MLTX Company Overview & Business Description
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
Key Information
Current Trend for MLTX
An assessment of the current trend environment for MLTX, based on the latest closing price data and intended to describe the market context heading into the next trading session.
As of 2025-12-24, the current trend for MLTX is an Indeterminate Transition Phase (Unclear Direction).
Daily and weekly trends are conflicting, reducing directional conviction and making directional trading less favorable at this stage.
- The weekly environment remains bearish, suggesting that any daily rallies may face structural overhead resistance.
- Price is currently compressing tightly (optimal low-risk zone), sitting -0.03 ATR away from the adaptive KAMA baseline.
- The market is maintaining a healthy 'Higher-High, Higher-Low' sequence, confirming buyer control.
Explore More Data
Adaptive Trend Model · Daily & Weekly (2025-12-24 ET)
This model uses an adaptive trend algorithm based on daily and weekly price data to identify whether a stock is in an uptrend, downtrend, or consolidation over a multi-week to multi-month horizon. Compared with traditional moving-average systems, it filters short-term noise more effectively, captures trend continuation more reliably, and provides a stronger basis for position sizing and risk-management decisions such as stop-loss and take-profit levels.
As of 2025-12-24, MLTX in a non-directional consolidation; Long-term trend is bearish.
Trend Strength: MLTX last closed at 13.87, trading 0.1 ATR above the adaptive KAMA baseline (13.79). Technical Classification: Non-Directional / Range-Bound.
Trend Score: Technical Score: 35/100. Classification: Sideways. Alignment: Indeterminate. Logic: Price action is range-bound or lacking sufficient slope for trend confirmation.
SuperTrend Risk: Structural Support: Adaptive SuperTrend at 12.20. This level serves as the calculated invalidation point for the current upward structure.
Risk Skew: Multi-timeframe risk skew is currently assessed as Non-Directional. Price is oscillating within a low-momentum range. Risk is two-sided, favoring mean-reversion strategies over trend-following.
Key Levels: Key technical references: Spot 13.87, KAMA 13.79.